Bexicaserin

贝卡色林

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameBexicaserin
Drug Alias NameLP-352AN-352LP352
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2c (5-HT2c) receptor agonists
TargetsSerotonin 2c (5-HT2c) receptor
Therapy Area/IndicationsDevelopmental and epileptic encephalopathyDevelopmental DisabilitiesSeizures +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLongboard Health Holdings Llc
China Registration ClassN/A

Develop Information

Active CompaniesAvema Pharma SolutionsLongboard Pharmaceuticals IncLongboard Health Holdings Llc +[4] 
Inactive CompaniesN/A
Active IndicationsDevelopmental and epileptic encephalopathyDevelopmental DisabilitiesSeizures +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank